Raj Gaji and his team at Virginia Tech were staring at a parasite that hijacks cells in the most dramatic way—building babies inside itself until the mother bursts. This is how Toxoplasma gondii, a microbe lurking in about one-third of humanity, spreads through the body. For most, it’s harmless, lying quiet in the brain. But for people with weakened immune systems, it can roar back to life, causing severe illness and even death. Now, Gaji’s team has found a weak spot: a protein called DDP that the parasite can’t live without.
DDP is like a construction manager for the parasite’s offspring. Toxoplasma doesn’t split like human cells. Instead, it builds two new parasites inside itself, using a scaffold called the inner membrane complex. DDP delivers the materials for that scaffold from the cell’s shipping center—the Golgi—to the growing daughters. Without DDP, the parasite copies its DNA but can’t assemble the next generation. It’s like having all the bricks but no crane to build the house.
What makes DDP so promising is that human cells don’t have it. They have parts of it—one molecular block or the other—but never the full combination. This unique pairing, called a DIX-DnaJ domain, exists only in Toxoplasma and its parasitic cousins. That means a drug targeting DDP could stop the parasite without harming the patient. The team proved its importance by tagging the protein so it breaks down when a chemical is added. When DDP vanished, reproduction stopped. When they restored it, the parasites started building again.
Even better, the discovery might stretch beyond Toxoplasma. When the researchers swapped in the version of DDP from Neospora caninum—a parasite that causes miscarriages in cattle and brain disease in dogs—it worked just as well. This hints that one drug could fight multiple parasites affecting both people and animals.
There’s no vaccine for Toxoplasma, and current drugs are toxic or ineffective against the dormant form. A treatment targeting DDP wouldn’t just ease symptoms—it could stop the damage at its source. "If you can develop a small-molecule drug that can target this protein and make it nonfunctional, then you have a drug that can treat the pathology caused by this parasite," Gaji said. For millions living with the threat of reactivation, that hope is now one step closer to reality.
